60 Recruiting Multiple Myeloma Phase 2 Clinical Trials
Active phase 2 studies for multiple myeloma enrolling across the USA. Verify eligibility and contact site coordinators.
All Multiple Myeloma studiesPhase 2 Studies for Multiple Myeloma
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
View Study & Checklist ➔A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
📍 Cross Cancer Institute — Edmonton, Alberta
View Study & Checklist ➔Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View Study & Checklist ➔Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
📍 University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
View Study & Checklist ➔2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Univ of Colorado Cancer Center /ID# 167331 — Aurora, Colorado
View Study & Checklist ➔Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
📍 Weill Cornell Medicine - Multiple Myeloma Center — New York, New York
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
View Study & Checklist ➔A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
📍 Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
📍 University of Alabama Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
View Study & Checklist ➔A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Salvador, Estado de Bahia
View Study & Checklist ➔Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
📍 HonorHealth Cancer Transplant Institute — Scottsdale, Arizona
View Study & Checklist ➔Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 The University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
View Study & Checklist ➔Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
📍 University of Rochester Medical Center — Rochester, New York
View Study & Checklist ➔A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
📍 University Of California San Diego — San Diego, California
View Study & Checklist ➔Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
📍 University of Nebraska Medical Center — Omaha, Nebraska
View Study & Checklist ➔KRDI in Transplant-Eligible MM
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔CAR- PRISM (PRecision Intervention Smoldering Myeloma)
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
📍 Memorial Sloan Kettering Basking Ridge (Consent and Followup) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Colorado — Aurora, Colorado
View Study & Checklist ➔Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Boston, Massachusetts
View Study & Checklist ➔A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
📍 University of Miami — Miami, Florida
View Study & Checklist ➔Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
📍 Weill Cornell Medical College — New York, New York
View Study & Checklist ➔Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Elimination of Minimal Residual Disease After Transplant
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
📍 Yale New Haven Hospital — New Haven, Connecticut
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
📍 238995 — Atlanta, Georgia
View Study & Checklist ➔A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
📍 University of Iowa Hospital and Clinics — Iowa City, Iowa
View Study & Checklist ➔A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680 — San Francisco, California
View Study & Checklist ➔Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
View Study & Checklist ➔Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
📍 NYU Langone Health Perlmutter Cancer Center - Sunset Park — Brooklyn, New York
View Study & Checklist ➔A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
📍 University of Miami — Miami, Florida
View Study & Checklist ➔